Temozolomide in uterine leiomyosarcomas

Gynecologic Oncology

Volumn 98, Issue 1, 2005, Pages 99-103

  Anderson, Sibyl ^a   Aghajanian, Carol ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Temozolomide; Uterine leiomyosarcomas

Indexed keywords

DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; TEMOZOLOMIDE;

ADULT; AGED; CANCER DIAGNOSIS; CANCER STAGING; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LEIOMYOSARCOMA; METASTASIS; NAUSEA; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; REVIEW; TOXICITY; UTERUS SARCOMA; VOMITING;

EID: 20644463697     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.03.018     Document Type: Article

References (16)

1. B.l. Harlow, N.s. Weis, and S. Lofton The epidemiology of sarcomas of the uterus J. Natl. Cancer Inst. 76 1986 399 402
2. M.M. Leitao, Y. Sonoda, M.F. Brennan, R.R. Barakat, and D.S. Chi Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus Gynecol. Oncol. 9 2003 209 212
3. S.E. Brooks, M. Zhan, T. Cote, and C.R. Baquet Surveillance, epidemiology and end results analysis if 2677 cases of uterine sarcoma 1989-1999 Gynecol. Oncol. 93 2004 204 208
4. H.B. Muss, B. Bundy, P.J. DiSaia, H.D. Homesley, W.C. Fowler Jr., and W. Creasman Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide: a phase III trial of the Gynecologic Oncology Group Cancer 55 1985 1648 1653
5. J.M. Buesa, H.T. Mouridsen, A.T. van Oosterom, J. Verweij, T. Tagener, and W. Steward High dose DTIC in advanced soft-tissue sarcomas in the adult: a phase II study of the EORTC soft tissue and bone sarcoma group Ann. Oncol. 2 1991 307 309
6. K.Y. Look, A. Sandler, J.A. Blessing, J.A. Lucci III, P.G. Rose Gynecologic Oncology Group (GOG) study Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study Gynecol. Oncol. 92 2004 644 647
7. G.P. Sutton, J.A. Blessing, R.J. Barrett, and R. McGehee Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Group (GOG) study Am. J. Obstet. Gynecol. 166 1992 556 559
8. M.L. Hensley, R. Maki, E. Venkatraman, G. Geller, M. Lovegren, and C. Aghajanian Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial J. Clin. Oncol. 12 15 2002 (Jun. 20) 2824 2831
9. C.S. Brock, E.S. Newlands, S.R. Wedge, M. Bower, H. Evans, and I. Colquhoun Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res. 58 1998 4363 4367
10. W.J. Hwu, S. Krown, K.S. Panageas, J.H. Menell, P.B. Chapman, and P.O. Livingston Temozolomide plus Thalidomide in patients with advanced melanoma: results of a dose-finding trial J. Clin. Oncol. 20 2002 2610 2615
11. M. Van Glabbeke, J. Verweij, I. Judson, and O.S. Nielsen EORTC soft tissue and bone sarcoma group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur. J. Cancer 38 2002 543 549
12. B.L. Harlow, N.S. Weiss, and S. Lofton The epidemiology of sarcomas of the uterus J. Natl. Cancer Inst. 76 1986 399 402
13. P.J. Woll, I. Judson, S.M. Lee, S. Rodenhuis, O.S. Nielsen, and J.M. Buesa Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group Eur. J. Cancer 35 1999 410 412
14. S.M. Talbot, M.L. Keohan, M. Hesdorffer, R. Orrico, E. Bagiella, and A.B. Troxel A phase II trial of Temozolomide in patients with unresectable or metastatic soft tissue sarcoma Cancer 98 2003 1942 1946
15. J.C. Trent, J. Beach, M.A. Burgess, N. Papadopolous, L.L. Chen, and R.S. Benjamin A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas Cancer 98 2003 2693 2699
16. Del Muro X, Lopez Pousa A, Buesa JM, Martin J, Poveda A, Bover I, Escudero P, Trufero JM, Casado A. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcomas: a phase II trial of the Spanish Group for Research on Sarcomas. CTOS; 2001 s33 [Abstract].